查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2100326

不可切除肝細胞癌市場－2026-2032年全球市場預測

Unresectable Hepatocellular Carcinoma Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，不可切除的肝細胞癌市場將成長至 53.5 億美元，複合年成長率為 13.79%。

主要市場統計數據
基準年 2025 21.6億美元
預計年份：2026年 24.3億美元
預測年份：2032年 53.5億美元
複合年成長率 (%) 13.79%

不可切除的肝細胞癌（HMCC）在肝癌治療中佔據至關重要的地位，其定義為由於腫瘤負荷過重、血管侵犯、多發性病灶、肝功能儲備受損或晚期肝硬化等原因而無法透過手術切除的腫瘤。肝細胞癌是最常見的原發性肝癌，與慢性B型肝炎、慢性C型肝炎、酒精性肝病、代謝功能障礙相關的脂肪肝、黃麴毒素暴露、肝硬化密切相關。全球權威癌症和肝病機構的公共衛生證據檢驗，肝癌一直是全球癌症死亡的主要原因之一，而且相當一部分患者在確診時已不適合接受根治性手術。

對於無法切除的肝細胞癌，治療模式正從單一療法轉向綜合全身治療、局部和區域治療、影像學評估以及多學科腫瘤委員會決策。在以患者為中心的最佳化治療方案中，聯合治療免疫查核點抑制劑、抗血管生成療法、蛋白酪氨酸激酶抑製劑、放射性栓塞術、經動脈化療體外放射治療、特定病例的消融術以及最佳支持治療的重要性日益凸顯。產業重點關注的領域包括：最佳化臨床實踐中的治療順序、透過生物標記擴大醫療服務的可及性、縮短診斷時間、支持高風險族群的肝癌監測以及在實現持續腫瘤控制的同時維持肝功能。

治療方式的變革性改變。

隨著臨床實踐從標準化全身治療轉向更個人化、多學科的綜合管理，不可切除肝細胞癌的治療模式正在改變。國際肝癌指引越來越重視肝功能、體能狀態、腫瘤負荷、主要血管侵犯、肝外轉移、門靜脈高壓以及病患意願等因素，以此作為選擇治療方案的依據。這使得肝病學、介入放射學、腫瘤內科、放射腫瘤學、病理學、安寧療護和移植醫學等領域的專家在協作治療中發揮越來越重要的作用。

人工智慧（AI）的累積影響

人工智慧 (AI) 對不可切除肝細胞癌的整個治療過程正產生日益顯著的影響，從風險分層和影像學檢查到治療計劃制定和臨床工作流程最佳化，無所不包。在高風險肝病患者群體中，AI 模型可以整合人口統計資訊、實驗室檢查結果、病毒性肝炎狀態、纖維化標記、影像學觀察和縱向臨床數據，從而幫助早期識別需要加強後續觀察的患者。在放射學領域，人們正在研究深度學習和放射組學方法，以提高病灶檢測、肝臟分割、腫瘤特徵分析、血管侵犯評估以及區分存活腫瘤和治療後壞死組織的能力。

按地區分類的主要發現

在亞太地區，肝細胞癌的負擔極為沉重，這主要是由於多個國家慢性B型肝炎感染率持續居高不下，以及丙型肝炎、酒精性肝病、某些地區的黃麴毒素暴露和代謝性肝病等因素造成的。該地區高危險群眾大規模、疫苗接種率差異顯著、後續觀察服務可及性參差不齊，以及先進的全身和局部/區域治療手段的可及性也存在差異，這些因素都會影響無法手術切除的肝細胞癌的預後。中國、日本、韓國、印度、澳洲和東協各國的醫療環境差異極大，有的國家擁有先進的影像學檢查、放射性栓塞術、經動脈介入治療和免疫療法等先進技術，有的國家則醫療資源有限，可能導致診斷延誤。

關鍵群體特定見解

東協地區肝細胞癌的發病情況複雜多樣，乙型肝炎在某些人群中仍是重要因素，而丙型肝炎、飲酒、糖尿病、肥胖、特定環境下的黃麴毒素暴露以及監測系統的差異均會影響診斷和治療途徑。都市區三級醫療機構已日益配備免疫療法、標靶治療、經動脈治療、放射療法和先進影像技術，但農村地區的醫療資源取得、自付費用和經濟負擔仍影響著治療效果。協調實施疫苗接種、抗病毒治療、肝硬化監測和肝病篩檢對於降低晚期或不可切除肝癌的發生率至關重要。

主要國家概況

在美國，不可切除肝細胞癌的診療情況複雜，患者常伴隨丙型肝炎感染史、酒精性肝病、代謝功能障礙相關的脂肪肝、肥胖、糖尿病以及監測服務取得的差異。在加拿大，全民健保管道和專家溝通網路固然重要，但地理距離以及原住民和偏遠社區的醫療服務取得仍然是需要重點考慮的因素。在墨西哥和巴西，除了病毒性肝炎和酒精性肝病外，代謝風險因素也在增加，晚期診斷往往與篩檢手段不統一、溝通管道不暢以及難以找到專科醫生等問題相關。

為行業領導者提供的實用建議

產業領導者應優先考慮實證策略，以改善不可切除肝細胞癌患者的識別、治療順序、治療可及性和可衡量的療效。首要任務包括加強對肝硬化、慢性B型肝炎、慢性C型肝炎、酒精性肝病和代謝功能障礙相關脂肪肝患者的監測和溝通管道。早期發現可以降低晚期不可切除階段開始治療的患者比例，並增加符合根治性或疾病控制干預條件的患者數量。

調查方法

針對不可切除肝細胞癌，嚴謹的調查方法應結合對二手資料的檢驗、專家的初步驗證以及對臨床、流行病學、監管和醫療資訊取得途徑的系統分析。二手資料應包括同行評審的臨床實驗室檢測結果、肝癌治療指南、監管文件、公共衛生資料庫、癌症登記數據、肝炎監測數據、臨床實踐指南和衛生技術評估報告。優先考慮的證據來源應包括隨機對照試驗、Meta分析、真實世界隊列研究、系統綜述、藥物安全性監測數據以及來自權威性肝病和腫瘤組織的共識聲明。

結論

由於不可切除肝細胞癌（HMCC）臨床表現複雜、發現晚期、常伴隨基礎肝病以及治療方案的快速發展，因此它是肝癌治療領域的重中之重。免疫療法聯合治療、標靶治療、先進的局部和區域治療技術、成像技術的進步、多學科治療方案的發展以及人工智慧（AI）技術的應用，正在改變這一領域的治療格局。同時，預防和監測仍然至關重要，因為許多病例都與可改變或可控制的危險因子有關，例如B型肝炎、C型肝炎、酒精性肝病、肥胖、糖尿病和肝硬化。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 不可切除肝細胞癌市場：依治療類型分類

  • 放射線治療
    • 質子束療法
    • 體外放射治療
  • 局部和區域療法
    • 經動脈化療栓塞術
    • 經動脈放射性栓塞術
  • 全身性治療
    • 標靶治療
    • 免疫療法
    • 聯合治療

第8章：不可切除肝細胞癌市場：依治療方案分類

  • 第 1 行
  • 第二行
  • 第三行

第9章：不可切除肝細胞癌市場：依給藥途徑分類

  • 靜脈
  • 口服

第10章：不可切除肝細胞癌市場：依作用機轉分類

  • 抑制血管新生
  • 免疫調節
  • 抑制癌細胞增殖
  • 誘導細胞凋亡

第11章 不可切除肝細胞癌市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第12章 不可切除肝細胞癌市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 不可切除肝細胞癌市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 不可切除肝細胞癌市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 不可切除肝細胞癌市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Innovent Biologics, Inc.
  • Ipsen SA
  • Jazz Pharmaceuticals, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Johnson & Johnson Services, Inc
  • Kyowa Kirin Co., Ltd.
  • Merck KGaA
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zai Lab Limited
Product Code: MRR-742BD5184A85

The Unresectable Hepatocellular Carcinoma Market is projected to grow by USD 5.35 billion at a CAGR of 13.79% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.16 billion
Estimated Year [2026] USD 2.43 billion
Forecast Year [2032] USD 5.35 billion
CAGR (%) 13.79%

Unresectable hepatocellular carcinoma represents a critical segment of liver cancer care, defined by tumors that cannot be removed surgically because of tumor burden, vascular invasion, multifocal disease, poor liver reserve, or advanced underlying cirrhosis. Hepatocellular carcinoma is the most common primary liver cancer and is strongly associated with chronic hepatitis B, chronic hepatitis C, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, aflatoxin exposure, and cirrhosis. Verified public health evidence from global cancer and liver disease authorities consistently identifies liver cancer among the leading causes of cancer mortality worldwide, with a high proportion of patients diagnosed beyond curative surgical eligibility.

The treatment paradigm for unresectable hepatocellular carcinoma has moved beyond single-modality care toward integrated systemic therapy, locoregional therapy, imaging-driven assessment, and multidisciplinary tumor board decision-making. Immune checkpoint inhibitor combinations, anti-angiogenic strategies, tyrosine kinase inhibitors, radioembolization, transarterial chemoembolization, external beam radiotherapy, ablation in select cases, and best supportive care are increasingly considered within patient-specific pathways. Key industry priorities include improving real-world treatment sequencing, expanding access to biomarker-informed care, reducing time to diagnosis, supporting liver cancer surveillance among high-risk populations, and preserving liver function while pursuing durable tumor control.

Transformative Shifts in the Treatment Landscape

The unresectable hepatocellular carcinoma landscape is undergoing transformative change as clinical practice shifts from uniform systemic treatment to more individualized and multidisciplinary management. International liver cancer guidelines increasingly emphasize liver function, performance status, tumor burden, macrovascular invasion, extrahepatic spread, portal hypertension, and patient preference when selecting treatment. This has elevated the role of hepatology, interventional radiology, oncology, radiation oncology, pathology, palliative care, and transplant expertise in coordinated care.

A major shift is the growing use of immunotherapy-based combinations as preferred first-line options for eligible patients, supported by phase III evidence showing survival and response advantages over older systemic standards in defined populations. At the same time, targeted therapies remain essential for patients who are ineligible for immunotherapy, have autoimmune disease, require later-line treatment, or experience progression. Locoregional therapies are also being refined through selective delivery, dosimetry, combination strategies, and better patient selection. The emergence of combination approaches involving systemic therapy with transarterial or radiation-based interventions is creating new clinical questions around timing, safety, hepatic decompensation risk, bleeding risk, and durable response assessment.

Another defining shift is the growing importance of surveillance and early detection. Many patients with hepatocellular carcinoma are diagnosed at stages where curative surgery is not feasible, particularly when cirrhosis surveillance is inconsistent. Health systems are therefore focusing on ultrasound-based surveillance, alpha-fetoprotein testing where appropriate, hepatitis B vaccination, antiviral treatment for hepatitis B and hepatitis C, alcohol harm reduction, and metabolic liver disease management. These preventive and diagnostic strategies directly influence the future clinical burden of unresectable disease.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing unresectable hepatocellular carcinoma across the care continuum, from risk stratification and imaging interpretation to treatment planning and clinical workflow optimization. In high-risk liver disease populations, AI-enabled models can integrate demographics, laboratory values, viral hepatitis status, fibrosis markers, imaging signals, and longitudinal clinical data to support earlier identification of patients needing intensified surveillance. In radiology, deep learning and radiomics approaches are being studied to improve lesion detection, liver segmentation, tumor characterization, vascular invasion assessment, and differentiation between viable tumor and post-treatment necrosis.

AI also has practical implications for locoregional and radiation-based treatment planning. Automated tumor and organ-at-risk contouring, image registration, dose optimization, and response quantification can help standardize workflows and reduce interobserver variability. In systemic therapy, machine learning may support prediction of treatment response, immune-related adverse event risk, liver decompensation, and treatment discontinuation, although clinical adoption depends on external validation, transparent model design, regulatory compliance, privacy protection, and integration into electronic health records.

The cumulative impact of AI is strongest when it improves decision confidence rather than replacing clinical judgment. For industry stakeholders, the most important opportunities are validated AI tools that support hepatocellular carcinoma surveillance, multidisciplinary case review, real-world evidence generation, trial matching, biomarker discovery, toxicity monitoring, and patient follow-up. Key barriers remain data heterogeneity, limited representation of diverse liver disease etiologies, inconsistent imaging protocols, fragmented data systems, algorithm bias, and the need for prospective clinical utility evidence.

Key Regional Insights

Asia-Pacific carries a substantial hepatocellular carcinoma burden because chronic hepatitis B infection remains highly prevalent in several countries, while hepatitis C, alcohol-related liver disease, aflatoxin exposure in selected areas, and metabolic liver disease also contribute. The region's large at-risk population, differences in vaccination coverage, variable access to surveillance, and uneven availability of advanced systemic and locoregional therapies shape outcomes in unresectable disease. China, Japan, South Korea, India, Australia, and ASEAN countries demonstrate highly diverse care environments, ranging from advanced imaging, radioembolization, transarterial procedures, and immunotherapy access to resource-constrained pathways where diagnosis may occur late.

North America is characterized by strong specialist infrastructure, broad use of guideline-based systemic therapy, access to interventional radiology, and expanding attention to liver cancer linked to metabolic dysfunction-associated steatotic liver disease. The United States and Canada benefit from established oncology and hepatology networks, although disparities persist by insurance status, geography, Indigenous health inequities, rural access, transplant referral variation, and viral hepatitis screening gaps. Latin America faces a mixed epidemiologic profile, with hepatitis B, hepatitis C, alcohol-related liver disease, obesity, diabetes, and uneven surveillance contributing to advanced-stage presentation. Brazil and Mexico are important regional care centers, but access to high-cost therapies, molecular diagnostics, advanced imaging, and specialized liver cancer services remains inconsistent.

Europe has a mature hepatocellular carcinoma care ecosystem supported by liver cancer guidelines, multidisciplinary tumor boards, viral hepatitis elimination initiatives, cancer registries, and established reimbursement structures in many countries. However, southern and eastern parts of the region continue to face varied access to screening and advanced therapy. The Middle East shows growing need for specialized liver cancer care as hepatitis-related disease, fatty liver disease, diabetes, and obesity converge, while GCC countries are investing in tertiary oncology, interventional radiology, and transplant-linked infrastructure. Africa faces the most pronounced access challenges, including high hepatitis B prevalence in many areas, aflatoxin exposure in selected regions, limited surveillance, constrained pathology and imaging capacity, insufficient antiviral access, and delayed diagnosis, making prevention, vaccination, antiviral treatment, and scalable diagnostics central to reducing unresectable hepatocellular carcinoma impact.

Key Group Insights

ASEAN countries represent a diverse hepatocellular carcinoma environment where hepatitis B remains an important driver in several populations, while hepatitis C, alcohol use, diabetes, obesity, aflatoxin exposure in selected settings, and variable surveillance systems influence diagnosis and treatment pathways. Urban tertiary centers are increasingly capable of delivering immunotherapy, targeted therapy, transarterial procedures, radiation-based treatment, and advanced imaging, but rural access, out-of-pocket costs, and affordability continue to shape outcomes. Coordinated vaccination, antiviral treatment, cirrhosis surveillance, and liver disease screening remain decisive for reducing late-stage and unresectable presentation.

The GCC is marked by rapid healthcare infrastructure development, increasing oncology specialization, and a rising burden of metabolic liver disease linked to obesity and diabetes, alongside viral hepatitis among some populations. These countries are strengthening tertiary cancer centers, digital health infrastructure, and cross-border referral pathways, creating opportunities for standardized multidisciplinary hepatocellular carcinoma care. The European Union benefits from structured regulatory frameworks, guideline harmonization, hepatitis elimination strategies, health technology assessment processes, and clinical research networks that support consistent adoption of evidence-based therapies, although reimbursement timelines and access to innovative treatment can vary between member states.

BRICS countries collectively account for a large share of the global population at risk for liver cancer, with China and India playing central roles because of population scale and viral hepatitis burden, while Brazil, Russia, and South Africa add distinct patterns involving hepatitis, alcohol-related liver disease, metabolic disease, aflatoxin exposure in selected regions, and healthcare access variability. The G7 group is characterized by advanced oncology systems, strong trial participation, high imaging capability, established pharmacovigilance systems, and increasing focus on real-world evidence, yet it is also experiencing rising hepatocellular carcinoma linked to metabolic liver disease and aging populations. NATO countries overlap with many high-income health systems and emphasize security of pharmaceutical supply chains, clinical readiness, digital health infrastructure, and cross-border research collaboration, all of which affect access and resilience in advanced liver cancer care.

Key Country Insights

The United States has a complex unresectable hepatocellular carcinoma landscape driven by hepatitis C legacy infections, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, obesity, diabetes, and disparities in surveillance access. Canada emphasizes universal healthcare pathways and specialist referral networks, but geographic distance and access for Indigenous and remote communities remain important considerations. Mexico and Brazil face growing metabolic risk factors alongside viral hepatitis and alcohol-related liver disease, with advanced-stage diagnosis often linked to uneven screening, fragmented referral pathways, and specialist availability.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have established hepatology-oncology collaboration, interventional radiology capacity, liver imaging expertise, and access to guideline-supported systemic therapy, while each country faces increasing liver cancer relevance from obesity, diabetes, alcohol use, and an aging population. Germany and France are notable for strong tertiary care and research infrastructure, Italy and Spain have significant cirrhosis-linked hepatocellular carcinoma experience, and the United Kingdom continues to focus on earlier diagnosis, hepatitis C elimination, and reducing regional cancer care variation. Russia has a mixed burden involving viral hepatitis, alcohol-related liver disease, and variable access to advanced diagnostics and therapies across regions.

China remains one of the most important countries for unresectable hepatocellular carcinoma because chronic hepatitis B has historically contributed heavily to liver cancer incidence, although vaccination and antiviral strategies are changing long-term risk patterns. India faces a broad and heterogeneous burden involving hepatitis B, hepatitis C, alcohol-related liver disease, and metabolic risk, with access differences between metropolitan tertiary centers and smaller cities or rural areas. Japan has extensive experience in surveillance, imaging, locoregional therapy, and systemic treatment, with a historical hepatitis C burden and a growing metabolic liver disease component. Australia benefits from advanced cancer care infrastructure and guideline-based access, while continuing to address liver cancer risks among viral hepatitis populations, people with metabolic liver disease, Aboriginal and Torres Strait Islander communities, and other underserved groups. South Korea has strong national screening practices for high-risk groups, advanced hospital infrastructure, and a significant clinical focus on hepatitis B-associated hepatocellular carcinoma.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based strategies that improve patient identification, treatment sequencing, access, and measurable outcomes in unresectable hepatocellular carcinoma. The first priority is strengthening surveillance and referral pathways for patients with cirrhosis, chronic hepatitis B, chronic hepatitis C, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease. Earlier detection can reduce the proportion of patients entering care with advanced, unresectable disease and can improve eligibility for curative or disease-controlling interventions.

Stakeholders should invest in multidisciplinary care models that connect hepatology, oncology, interventional radiology, radiology, pathology, palliative care, transplant services, clinical pharmacy, and nursing navigation. Treatment algorithms should reflect liver function, bleeding risk, autoimmune status, portal hypertension, tumor stage, patient goals, and local treatment availability. Real-world evidence programs should be designed to evaluate sequencing after immunotherapy-based regimens, outcomes in Child-Pugh B populations, tolerability in older adults, management of immune-related toxicities, quality-of-life outcomes, and integration of locoregional therapy with systemic treatment.

Additional priorities include expanding biomarker research, validating AI-enabled imaging and risk prediction tools, improving clinical trial diversity, supporting hepatitis B vaccination and antiviral treatment, reducing financial toxicity, strengthening patient navigation, and ensuring patient education around treatment expectations and adverse event reporting. Leaders should also build resilient supply chains for essential oncology drugs, contrast imaging, interventional radiology materials, radiation planning resources, diagnostic testing, and supportive care therapies to reduce interruptions in advanced liver cancer management.

Research Methodology

A rigorous research methodology for unresectable hepatocellular carcinoma should combine secondary evidence review, primary expert validation, and structured analysis of clinical, epidemiologic, regulatory, and access-related information. Secondary research should include peer-reviewed clinical trial publications, liver cancer treatment guidelines, regulatory documents, public health databases, cancer registry outputs, hepatitis surveillance data, clinical practice recommendations, and health technology assessment reports. Priority evidence sources include randomized trials, meta-analyses, real-world cohort studies, systematic reviews, pharmacovigilance data, and consensus statements from recognized liver disease and oncology organizations.

Primary research should involve structured interviews with medical oncologists, hepatologists, interventional radiologists, radiation oncologists, pathologists, clinical pharmacists, payer experts, patient advocacy stakeholders, and hospital administrators. These interviews help validate treatment adoption patterns, barriers to access, referral bottlenecks, toxicity management practices, sequencing decisions, and regional variations in care. Analytical triangulation should be used to reconcile clinical evidence, real-world practice, and policy conditions without relying on unsupported assumptions.

The methodology should also evaluate treatment pathways by disease stage, liver function status, eligibility for immunotherapy, viral hepatitis status, performance status, portal hypertension, bleeding risk, and availability of locoregional intervention. Data quality should be assessed through source credibility, publication recency, population relevance, sample size, endpoint validity, and consistency across geographies. Ethical and compliance considerations are essential when interpreting patient-level data, particularly in AI applications, real-world evidence studies, registry linkage, and digital health platforms.

Conclusion

Unresectable hepatocellular carcinoma is a high-priority area in liver cancer care because it combines significant clinical complexity, late-stage presentation, underlying liver disease, and rapidly evolving treatment options. The field is being reshaped by immunotherapy-based combinations, targeted therapies, advanced locoregional techniques, improved imaging, multidisciplinary treatment planning, and emerging artificial intelligence applications. At the same time, prevention and surveillance remain central because many cases are linked to modifiable or manageable risk factors, including hepatitis B, hepatitis C, alcohol-related liver disease, obesity, diabetes, and cirrhosis.

Regional and country-level differences in viral hepatitis prevalence, metabolic risk, healthcare infrastructure, reimbursement, specialist access, imaging capacity, and screening programs strongly influence patient outcomes. Industry stakeholders that focus on earlier detection, validated innovation, equitable access, robust real-world evidence, and integrated care delivery will be best positioned to address the unmet needs of patients with unresectable hepatocellular carcinoma. Sustainable progress will depend on aligning clinical evidence with practical implementation across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Unresectable Hepatocellular Carcinoma Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Radiation Therapy
    • 7.2.1. Proton Therapy
    • 7.2.2. External Beam Radiation Therapy
  • 7.3. Locoregional Therapy
    • 7.3.1. Transarterial Chemoembolization
    • 7.3.2. Transarterial Radioembolization
  • 7.4. Systemic Therapy
    • 7.4.1. Targeted Therapy
    • 7.4.2. Immunotherapy
    • 7.4.3. Combination Therapy

8. Unresectable Hepatocellular Carcinoma Market, by Line Of Therapy

  • 8.1. Introduction
  • 8.2. First Line
  • 8.3. Second Line
  • 8.4. Third Line

9. Unresectable Hepatocellular Carcinoma Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral

10. Unresectable Hepatocellular Carcinoma Market, by Mechanism of Action

  • 10.1. Introduction
  • 10.2. Angiogenesis Inhibition
  • 10.3. Immune Modulation
  • 10.4. Tumor Cell Proliferation Inhibition
  • 10.5. Apoptosis Induction

11. Unresectable Hepatocellular Carcinoma Market, by End User

  • 11.1. Introduction
  • 11.2. Home Care Settings
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Unresectable Hepatocellular Carcinoma Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Unresectable Hepatocellular Carcinoma Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Unresectable Hepatocellular Carcinoma Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Unresectable Hepatocellular Carcinoma Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Amgen Inc.
  • 17.3. AstraZeneca PLC
  • 17.4. Bayer AG
  • 17.5. Bristol-Myers Squibb Company
  • 17.6. CStone Pharmaceuticals
  • 17.7. Daiichi Sankyo Company, Limited
  • 17.8. Eisai Co., Ltd.
  • 17.9. Eli Lilly and Company
  • 17.10. Exelixis, Inc.
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. Gilead Sciences, Inc.
  • 17.13. GlaxoSmithKline plc
  • 17.14. Innovent Biologics, Inc.
  • 17.15. Ipsen S.A.
  • 17.16. Jazz Pharmaceuticals, Inc.
  • 17.17. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 17.18. Johnson & Johnson Services, Inc
  • 17.19. Kyowa Kirin Co., Ltd.
  • 17.20. Merck KGaA
  • 17.21. Novartis AG
  • 17.22. Ono Pharmaceutical Co., Ltd.
  • 17.23. Pfizer Inc.
  • 17.24. Shanghai Junshi Biosciences Co., Ltd.
  • 17.25. Takeda Pharmaceutical Company Limited
  • 17.26. Teva Pharmaceutical Industries Ltd.
  • 17.27. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RADIATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROTON THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROTON THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROTON THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EXTERNAL BEAM RADIATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EXTERNAL BEAM RADIATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EXTERNAL BEAM RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LOCOREGIONAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LOCOREGIONAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LOCOREGIONAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSARTERIAL RADIOEMBOLIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSARTERIAL RADIOEMBOLIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSARTERIAL RADIOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SYSTEMIC THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYSTEMIC THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYSTEMIC THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THIRD LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THIRD LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL THIRD LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANGIOGENESIS INHIBITION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANGIOGENESIS INHIBITION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANGIOGENESIS INHIBITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNE MODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNE MODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNE MODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TUMOR CELL PROLIFERATION INHIBITION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TUMOR CELL PROLIFERATION INHIBITION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TUMOR CELL PROLIFERATION INHIBITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL APOPTOSIS INDUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL APOPTOSIS INDUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL APOPTOSIS INDUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 204. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)

TABLE 30